New cancer drug enters human testing for patients out of options
NCT ID NCT06092580
Summary
This is the first study in humans testing an experimental drug called AWT020 for people with advanced cancer that has spread and no longer responds to standard treatments. The main goals are to find a safe dose and see how the drug behaves in the body. About 60 participants will receive the drug by IV infusion until their cancer worsens or they leave the study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
ICON Cancer Center South Brisbane
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Monash Medical Centre
RECRUITINGClayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITINGBedford Park, South Australia, 5042, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.